New FDA Rule Boosts Access to Life-Changing Schizophrenia Drug

New FDA Rule Boosts Access to Life-Changing Schizophrenia Drug

The FDA implemented a significant change to make clozapine, the only prescription drug for treatment-resistant schizophrenia, more widely available. Patients once had to undergo frequent blood tests before they could have their prescriptions filled because of a potentially lethal but rare side effect, neutropenia, which decreases white blood cell levels and compromises the immune system. But after years of complaint from doctors, pharmacists, and families, the FDA eliminated this requirement.

FDA Greenlights Real-Time Adaptive DBS to Improve Parkinson’s Treatment

FDA Greenlights Real-Time Adaptive DBS to Improve Parkinson’s Treatment

Medtronic received FDA approval for its BrainSense Adaptive Deep Brain Stimulation (aDBS) system and the BrainSense Electrode Identifier (EI) to treat patients with Parkinson’s disease. This technology represents a major step forward in treatment by allowing the device to adapt stimulation automatically in real-time based on the neural activity of the patient.

FDA Greenlights New Meningococcal Vaccine for Broader Protection

FDA Greenlights New Meningococcal Vaccine for Broader Protection

The study introduces a novel method of acknowledging the important connection between a pregnant woman’s peri- and post-natal mental health and cardiac health. Doctors in the past have most frequently taken into account body functions like blood pressure and cholesterol when measuring a woman’s cardiovascular health.

Psychological Health in Perinatal Care: A Focus on Maternal Heart Health

Psychological Health in Perinatal Care: A Focus on Maternal Heart Health

The study introduces a novel method of acknowledging the important connection between a pregnant woman’s peri- and post-natal mental health and cardiac health. Doctors in the past have most frequently taken into account body functions like blood pressure and cholesterol when measuring a woman’s cardiovascular health.

Dapagliflozin-Induced Immune Hemolytic Anemia: A Case Report

Dapagliflozin-Induced Immune Hemolytic Anemia: A Case Report

This case report details an extremely rare disease called drug-induced immune hemolytic anemia (DIIHA) that developed in a 52-year-old man once he started using the drug dapagliflozin (Farxiga), a drug often prescribed for diabetes. The report speculates that this could be the first to link this particular drug to this unusual disorder. DIIHA is a dangerous side effect wherein the immune system abnormally reacts against and destroys red blood cells upon exposure to a drug. While extremely uncommon, affecting 1-2 people per million individuals per year, it is life-threatening unless treated.